Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ADC THERAPEUTICS SA

(ADCT)
  Report
Delayed Nyse  -  04:00 2022-12-05 pm EST
3.510 USD   -3.04%
11/28Biocytogen Enters into Antibody Agreement with ADC Therapeutics
BU
11/28ADC Therapeutics, Biocytogen Pharmaceuticals Sign Antibody License Deal for Tumor Targets
MT
11/14Sobi to present new data at the ASH 2022 Annual Meeting
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

ADC Therapeutics, Swedish Orphan Biovitrum's Co-Developed Drug Recommended for EU Authorization

09/16/2022 | 06:11am EST

By Sabela Ojea


ADC Therapeutics SA and Swedish Orphan Biovitrum said Friday that a European Medicines Agency committee has recommended granting marketing authorization for their co-developed Zynlonta drug, aimed at treating patients with diffuse large b-cell lymphomas in Europe.

The companies said that the European Union's Committee for Medicinal Products for Human Use has a positive opinion on the treatment of this type of cancer, which begins in the lymphatic system.

The positive opinion from the CHMP is now referred to the European Commission for an approval decision, the companies said.


Write to Sabela Ojea at sabela.ojea@wsj.com


(END) Dow Jones Newswires

09-16-22 0811ET

Stocks mentioned in the article
ChangeLast1st jan.
ADC THERAPEUTICS SA -3.04% 3.51 Delayed Quote.-82.62%
SWEDISH ORPHAN BIOVITRUM AB (PUBL) -1.56% 208 Delayed Quote.14.26%
All news about ADC THERAPEUTICS SA
11/28Biocytogen Enters into Antibody Agreement with ADC Therapeutics
BU
11/28ADC Therapeutics, Biocytogen Pharmaceuticals Sign Antibody License Deal for Tumor Targe..
MT
11/14Sobi to present new data at the ASH 2022 Annual Meeting
AQ
11/14Morgan Stanley Adjusts Price Target on ADC Therapeutics SA to $7 From $11, Maintains Eq..
MT
11/09BofA Securities Downgrades ADC Therapeutics to Neutral From Buy, Adjusts Price Target t..
MT
11/09RBC Cuts Price Target on ADC Therapeutics to $20 From $25, Notes Delay in Potential Cam..
MT
11/08Transcript : ADC Therapeutics SA, Q3 2022 Earnings Call, Nov 08, 2022
CI
11/08Earnings Flash (ADCT) ADC THERAPEUTICS SA Posts Q3 Revenue $76.3M
MT
11/08Earnings Flash (ADCT) ADC THERAPEUTICS SA Posts Q3 EPS $0.13
MT
11/08Adc Therapeutics : Purchase Agreement - Form 6-K
PU
More news
Analyst Recommendations on ADC THERAPEUTICS SA
More recommendations
Financials (USD)
Sales 2022 196 M - -
Net income 2022 -159 M - -
Net cash 2022 309 M - -
P/E ratio 2022 -1,73x
Yield 2022 -
Capitalization 289 M 289 M -
EV / Sales 2022 -0,10x
EV / Sales 2023 0,82x
Nbr of Employees 312
Free-Float 46,9%
Chart ADC THERAPEUTICS SA
Duration : Period :
ADC Therapeutics SA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ADC THERAPEUTICS SA
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 3,51 $
Average target price 14,17 $
Spread / Average Target 304%
EPS Revisions
Managers and Directors
Ameet Mallik President, Chief Executive Officer & Director
Jennifer Creel Chief Financial Officer
Ron Squarer Chairman
Patrick van Berkel Chief Scientific Officer
Joseph S. Camardo Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
ADC THERAPEUTICS SA-82.62%289
VERTEX PHARMACEUTICALS46.34%82 493
REGENERON PHARMACEUTICALS, INC.21.36%81 852
BIONTECH SE-35.33%41 250
WUXI APPTEC CO., LTD.-33.88%32 901
GENMAB A/S24.18%30 145